Overview

A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of KRP-104 in Patients With Type 2 Diabetes Inadequately Controlled on Metformin Alone

Status:
Completed

Trial end date:
2008-08-01

Target enrollment:

Participant gender:

Summary

To assess the safety and efficacy of chronic therapy with KRP-104, a novel DPP-IV inhibitor, in patients with Type 2 Diabetes on stable metformin therapy. In addition, an estimate of how much of the HbA1c response is attributable to nocturnal coverage will be explored.

Phase:

Phase 2

Details

Lead Sponsor:

ActivX Biosciences, Inc.

Collaborator:

Kyorin Pharmaceutical Co.,Ltd

Treatments:

Metformin